Vaccibody.com | Uncategorized
1
archive,paged,category,category-uncategorized,category-1,paged-4,category-paged-4,ajax_updown_fade,page_not_loaded,,qode-title-hidden,qode-child-theme-ver-,qode-theme-ver-16.6,qode-theme-bridge,disabled_footer_top,wpb-js-composer js-comp-ver-5.5.5,vc_responsive

Vaccibody is a vaccine company dedicated to the development of novel vaccines that overcome shortcomings of current vaccine technologies. The Company’s proprietary vaccine platform increases the antibody and T-cell responses leading to remarkably effective vaccines. Vaccibody plans to initiate its first clinical trial with a...

Vaccibody AS is pleased to announce that the U.S. Patent Office has Issued patent No. US 8,932,603 B2 covering the Vaccibody format which can be described as homodimeric modular constructs targeting vaccines to antigen presenting cells designed to increase the immune system’s antibody and T-cell...

Vaccibody AS today announces that the European Patent Office (EPO) has granted European patent No. 1599504 covering the Vaccibody format which can be described as homodimeric modular constructs targeting vaccines to antigen presenting cells designed to increase the immune system’s antibody and T-cell responses. This patent...

As Vaccibody is entering into a new development phase, the Board of Directors has initiated a search process for a new CEO with experience from clinical development and strategic partnering. On this background, Ole Henrik Brekke, CEO since 2006, has decided to leave the...

A report addressing solutions for strengthening the Norwegian biotechindustry was handed over to the Norwegian government May 20th. Vaccibody was the company being exemplified in the accompanying article in Dagens Næringsliv. Read the article here (Norwegian only)....

The Norwegian Cancer Society (NCS) has recently organized a investment fund for Norwegian companies with a focus on developing novel cancer therapies. With the promising development of VB10.16, Vaccibody’s therapeutic vaccine against HPV induced precancerous lesions,  NCS  has decided to place their first investment in...

New targeting vaccines for aquaculture based on the Vaccibody concept won 1st prize in Marine Innovation Day (MID) Innovation Award in a conference held in Bergen early in March. The vaccineproject run by researchers at the Norwegian Veterinary Institute and University of Oslo aims to utilize...